Diffusion-weighted MRI and liver metastases

Magnetic Resonance Imaging Clinics of North America

Volumn 18, Issue 3, 2010, Pages 451-464

  Chandarana, Hersh ^a   Taouli, Bachir ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Diffusion; Liver; Metastases; MRI

Indexed keywords

ECHOVIST; FLUORODEOXYGLUCOSE; GADOBENATE DIMEGLUMINE; GADOLINIUM; GADOLINIUM PENTETATE; GADOXETIC ACID; MANGAFODIPIR; PENTETIC ACID; SUPERPARAMAGNETIC IRON OXIDE;

BENIGN TUMOR; COLORECTAL CANCER; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; HEPATOGRAPHY; HUMAN; IMAGE ANALYSIS; IMAGE PROCESSING; IMAGE QUALITY; LIVER METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; OUTCOME ASSESSMENT; REVIEW; SENSITIVITY AND SPECIFICITY; SIGNAL DETECTION; TREATMENT RESPONSE;

DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; IMAGE ENHANCEMENT; LIVER; LIVER NEOPLASMS;

EID: 78649306861     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mric.2010.07.001     Document Type: Review

References (79)

1. Kasper H.U., Drebber U., Dries V., et al. Z Gastroenterol 2005, 43(10):1149-1157. [in German].
2. Baker M.E., Pelley R. Hepatic metastases: basic principles and implications for radiologists. Radiology 1995, 197(2):329-337.
3. Martinez L., Puig I., Valls C. Colorectal liver metastases: radiological diagnosis and staging. Eur J Surg Oncol 2007, 33(Suppl 2):S5-16.
4. Sharma S., Camci C., Jabbour N. Management of hepatic metastasis from colorectal cancers: an update. J Hepatobiliary Pancreat Surg 2008, 15(6):570-580.
5. Ruers T., Bleichrodt R.P. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002, 38(7):1023-1033.
6. Ravikumar T.S., Steele G.D. Hepatic cryosurgery. Surg Clin North Am 1989, 69(2):433-440.
7. Konopke R., Kersting S., Bergert H., et al. Contrast-enhanced ultrasonography to detect liver metastases: a prospective trial to compare transcutaneous unenhanced and contrast-enhanced ultrasonography in patients undergoing laparotomy. Int J Colorectal Dis 2007, 22(2):201-207.
8. Bartolotta T.V., Taibbi A., Midiri M., et al. Focal liver lesions: contrast-enhanced ultrasound. Abdom Imaging 2009, 34(2):193-209.
9. Quaia E., Bartolotta T.V., Midiri M., et al. Analysis of different contrast enhancement patterns after microbubble-based contrast agent injection in liver hemangiomas with atypical appearance on baseline scan. Abdom Imaging 2006, 31(1):59-64.
10. Kamel I.R., Fishman E.K. Recent advances in CT imaging of liver metastases. Cancer J 2004, 10(2):104-120.
11. Bonaldi V.M., Bret P.M., Reinhold C., et al. Helical CT of the liver: value of an early hepatic arterial phase. Radiology 1995, 197(2):357-363.
12. Francis I.R., Cohan R.H., McNulty N.J., et al. Multidetector CT of the liver and hepatic neoplasms: effect of multiphasic imaging on tumor conspicuity and vascular enhancement. AJR Am J Roentgenol 2003, 180(5):1217-1224.
13. Kanematsu M., Kondo H., Goshima S., et al. Imaging liver metastases: review and update. Eur J Radiol 2006, 58(2):217-228.
14. Soyer P., Poccard M., Boudiaf M., et al. Detection of hypovascular hepatic metastases at triple-phase helical CT: sensitivity of phases and comparison with surgical and histopathologic findings. Radiology 2004, 231(2):413-420.
15. Fazel R., Krumholz H.M., Wang Y., et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med 2009, 361(9):849-857.
16. Khalil H.I., Patterson S.A., Panicek D.M. Hepatic lesions deemed too small to characterize at CT: prevalence and importance in women with breast cancer. Radiology 2005, 235(3):872-878.
17. Schwartz L.H., Gandras E.J., Colangelo S.M., et al. Prevalence and importance of small hepatic lesions found at CT in patients with cancer. Radiology 1999, 210(1):71-74.
18. Krakora G.A., Coakley F.V., Williams G., et al. Small hypoattenuating hepatic lesions at contrast-enhanced CT: prognostic importance in patients with breast cancer. Radiology 2004, 233(3):667-673.
19. Erturk S.M., Ichikawa T., Fujii H., et al. PET imaging for evaluation of metastatic colorectal cancer of the liver. Eur J Radiol 2006, 58(2):229-235.
20. Ogunbiyi O.A., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997, 4(8):613-620.
21. Truant S., Huglo D., Hebbar M., et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005, 92(3):362-369.
22. Bipat S., van Leeuwen M.S., Comans E.F., et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005, 237(1):123-131.
23. Lai D.T., Fulham M., Stephen M.S., et al. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996, 131(7):703-707.
24. Sahani D.V., Kalva S.P., Fischman A.J., et al. Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol 2005, 185(1):239-246.
25. McFarland E.G., Mayo-Smith W.W., Saini S., et al. Hepatic hemangiomas and malignant tumors: improved differentiation with heavily T2-weighted conventional spin-echo MR imaging. Radiology 1994, 193(1):43-47.
26. Kelekis N.L., Semelka R.C., Woosley J.T. Malignant lesions of the liver with high signal intensity on T1-weighted MR images. J Magn Reson Imaging 1996, 6(2):291-294.
27. de Lange E.E., Mugler J.P.I.I.I., Bosworth J.E., et al. MR imaging of the liver: breath-hold T1-weighted MP-GRE compared with conventional T2-weighted SE imaging-lesion detection, localization, and characterization. Radiology 1994, 190(3):727-736.
28. Elsayes K.M., Narra V.R., Yin Y., et al. Focal hepatic lesions: diagnostic value of enhancement pattern approach with contrast-enhanced 3D gradient-echo MR imaging. Radiographics 2005, 25(5):1299-1320.
29. Quillin S.P., Atilla S., Brown J.J., et al. Characterization of focal hepatic masses by dynamic contrast-enhanced MR imaging: findings in 311 lesions. Magn Reson Imaging 1997, 15(3):275-285.
30. Cantwell C.P., Setty B.N., Holalkere N., et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 2008, 32(5):738-744.
31. Reimer P., Rummeny E.J., Daldrup H.E., et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997, 7(2):275-280.
32. Vogl T.J., Schwarz W., Blume S., et al. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 2003, 13(2):262-272.
33. Hammerstingl R., Huppertz A., Breuer J., et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008, 18(3):457-467.
34. Ward J., Robinson P.J., Guthrie J.A., et al. Liver metastases in candidates for hepatic resection: comparison of helical CT and gadolinium- and SPIO-enhanced MR imaging. Radiology 2005, 237(1):170-180.
35. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21(4):1104-1108.
36. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243(1):148-157.
37. Thomsen H.S. How to avoid nephrogenic systemic fibrosis: current guidelines in Europe and the United States. Radiol Clin North Am 2009, 47(5):871-875. vii.
38. Le Bihan D. Molecular diffusion nuclear magnetic resonance imaging. Magn Reson Q 1991, 7(1):1-30.
39. Bammer R. Basic principles of diffusion-weighted imaging. Eur J Radiol 2003, 45(3):169-184.
40. Chiu F.Y., Jao J.C., Chen C.Y., et al. Effect of intravenous gadolinium-DTPA on diffusion-weighted magnetic resonance images for evaluation of focal hepatic lesions. J Comput Assist Tomogr 2005, 29(2):176-180.
41. Choi J.S., Kim M.J., Choi J.Y., et al. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2009, 20(5):1052-1060.
42. Butts K., Riederer S.J., Ehman R.L., et al. Echo-planar imaging of the liver with a standard MR imaging system. Radiology 1993, 189(1):259-264.
43. Turner R., Le Bihan D., Chesnick A.S. Echo-planar imaging of diffusion and perfusion. Magn Reson Med 1991, 19(2):247-253.
44. Taouli B., Koh D.M. Diffusion-weighted MR imaging of the liver. Radiology 2010, 254(1):47-66.
45. Taouli B., Sandberg A., Stemmer A., et al. Diffusion-weighted imaging of the liver: comparison of navigator triggered and breathhold acquisitions. J Magn Reson Imaging 2009, 30(3):561-568.
46. Koh D.M., Takahara T., Imai Y., et al. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn Reson Med Sci 2007, 6(4):211-224.
47. Parikh T., Drew S.J., Lee V.S., et al. Focal liver lesion detection and characterization with diffusion-weighted MR imaging: comparison with standard breath-hold T2-weighted imaging. Radiology 2008, 246(3):812-822.
48. Kwee T.C., Takahara T., Koh D.M., et al. Comparison and reproducibility of ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging of the liver. J Magn Reson Imaging 2008, 28(5):1141-1148.
49. Nasu K., Kuroki Y., Nawano S., et al. Hepatic metastases: diffusion-weighted sensitivity-encoding versus SPIO-enhanced MR imaging. Radiology 2006, 239(1):122-130.
50. Taouli B., Vilgrain V., Dumont E., et al. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003, 226(1):71-78.
51. Padhani A.R., Liu G., Koh D.M., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11(2):102-125.
52. Hussain S.M., De Becker J., Hop W.C., et al. Can a single-shot black-blood T2-weighted spin-echo echo-planar imaging sequence with sensitivity encoding replace the respiratory-triggered turbo spin-echo sequence for the liver? An optimization and feasibility study. J Magn Reson Imaging 2005, 21(3):219-229.
53. Lewin M., Poujol-Robert A., Boelle P.Y., et al. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007, 46(3):658-665.
54. Taouli B., Tolia A.J., Losada M., et al. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007, 189(4):799-806.
55. Bruegel M., Gaa J., Waldt S., et al. Diagnosis of hepatic metastasis: comparison of respiration-triggered diffusion-weighted echo-planar MRI and five t2-weighted turbo spin-echo sequences. AJR Am J Roentgenol 2008, 191(5):1421-1429.
56. Coenegrachts K., Delanote J., Ter Beek L., et al. Improved focal liver lesion detection: comparison of single-shot diffusion-weighted echoplanar and single-shot T2 weighted turbo spin echo techniques. Br J Radiol 2007, 80(955):524-531.
57. Hardie A.D., Naik M., Hecht E.M., et al. Diagnosis of liver metastases: value of diffusion-weighted MRI compared with gadolinium-enhanced MRI. Eur Radiol 2010, 20(6):1431-1441.
58. Zech C.J., Herrmann K.A., Dietrich O., et al. Black-blood diffusion-weighted EPI acquisition of the liver with parallel imaging: comparison with a standard T2-weighted sequence for detection of focal liver lesions. Invest Radiol 2008, 43(4):261-266.
59. van den Bos I.C., Hussain S.M., Krestin G.P., et al. Liver imaging at 3.0 T: diffusion-induced black-blood echo-planar imaging with large anatomic volumetric coverage as an alternative for specific absorption rate-intensive echo-train spin-echo sequences: feasibility study. Radiology 2008, 248(1):264-271.
60. Koh D.M., Brown G., Riddell A.M., et al. Detection of colorectal hepatic metastases using MnDPDP MR imaging and diffusion-weighted imaging (DWI) alone and in combination. Eur Radiol 2008, 18(5):903-910.
61. Naganawa S., Sato C., Nakamura T., et al. Diffusion-weighted images of the liver: comparison of tumor detection before and after contrast enhancement with superparamagnetic iron oxide. J Magn Reson Imaging 2005, 21(6):836-840.
62. Low R.N., Gurney J. Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 2007, 25(4):848-858.
63. Ichikawa T., Haradome H., Hachiya J., et al. Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence. AJR Am J Roentgenol 1998, 170(4):1029-1034.
64. Namimoto T., Yamashita Y., Sumi S., et al. Focal liver masses: characterization with diffusion-weighted echo-planar MR imaging. Radiology 1997, 204(3):739-744.
65. Yamada I., Aung W., Himeno Y., et al. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999, 210(3):617-623.
66. Kim T., Murakami T., Takahashi S., et al. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR Am J Roentgenol 1999, 173(2):393-398.
67. Bruegel M., Holzapfel K., Gaa J., et al. Characterization of focal liver lesions by ADC measurements using a respiratory triggered diffusion-weighted single-shot echo-planar MR imaging technique. Eur Radiol 2008, 18(3):477-485.
68. Gourtsoyianni S., Papanikolaou N., Yarmenitis S., et al. Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol 2008, 18(3):486-492.
69. Liapi E., Geschwind J.F., Vossen J.A., et al. Functional MRI evaluation of tumor response in patients with neuroendocrine hepatic metastasis treated with transcatheter arterial chemoembolization. AJR Am J Roentgenol 2008, 190(1):67-73.
70. Buijs M., Kamel I.R., Vossen J.A., et al. Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 2007, 18(8):957-963.
71. Buijs M., Vossen J.A., Hong K., et al. Chemoembolization of hepatic metastases from ocular melanoma: assessment of response with contrast-enhanced and diffusion-weighted MRI. AJR Am J Roentgenol 2008, 191(1):285-289.
72. Koh D.M., Scurr E., Collins D., et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am J Roentgenol 2007, 188(4):1001-1008.
73. Cui Y., Zhang X.P., Sun Y.S., et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 2008, 248(3):894-900.
74. Sasaki M., Yamada K., Watanabe Y., et al. Variability in absolute apparent diffusion coefficient values across different platforms may be substantial: a multivendor, multi-institutional comparison study. Radiology 2008, 249(2):624-630.
75. Braithwaite A.C., Dale B.M., Boll D.T., et al. Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology 2009, 250(2):459-465.
76. Dale B.M., Braithwaite A.C., Boll D.T., et al. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol 2010, 45(2):104-108.
77. Koh D.M., Blackledge M., Collins D.J., et al. Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 2009, 19(11):2728-2738.
78. Luciani A., Vignaud A., Cavet M., et al. Liver cirrhosis: intravoxel incoherent motion MR imaging-pilot study. Radiology 2008, 249(3):891-899.
79. Patel J., Sigmund E.E., Rusinek H., et al. Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 2010, 31(3):589-600.